The FDA has scheduled a public workshop on April 8 to discuss clinical trials for antibacterial treatments of nontuberculous mycobacterial (NTM) disease.

The meeting will consider clinical trial elements, including endpoints. NTM disease often requires two to three drugs for effective treatment.

The public workshop will be held at FDA’s White Oak Campus in Silver Spring, MD, from 8:30 a.m. to 5 p.m.